ATX968 | DHX9 inhibitor

ATX968 chemical structure

Available Options

Size:PriceQuantity 
5 mg$90.00
25 mg$325.00
Request Quote / Bulk / Custom Size
Product Inquiry

ATX968 (2973395-71-8) is a potent (EC50’s: 3 nM ATPase; 60 nM circBRIP1), selective, and orally bioavailable inhibitor of DExH-box helicase 9 (DHX9; RNA helicase A), an important regulator of transcription, translation, and genomic stability.1 ATX968 selectively kills microsatellite instable colorectal cancer cells with deficient mismatch repair, but not microsatellite stable cells with proficient mismatch repair.2 Active in mouse xenograft (LS411N and SW480) models of microsatellite instable colorectal cancer.

References/Citations:

  1. Daniels et al. (2025), Discovery of ATX968: An Orally Available Allosteric Inhibitor of DHX9; J. Med. Chem. 68 9537
  2. Castro et al. (2025), A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair; Cancer Res. 85 758
2973395-71-8, ATX-968, ATX968, ATX968 supplier, DExH-box helicase 9 inhibitor, DHX9 inhibitor, RNA helicase A inhibitor

Safety Data Sheet:

Download Safety Data Sheet

Product Data Sheet:

Download Product Data Sheet

Materials provided by Focus Biomolecules are for laboratory research use only and are not intended for human or veterinary applications. Please note that we do not sell to individuals and that all orders placed by non-research organizations will incur a $20 restocking/refund fee

ATX968 (2973395-71-8) is a potent (EC50’s: 3 nM ATPase; 60 nM circBRIP1), selective, and orally bioavailable inhibitor of DExH-box helicase 9 (DHX9; RNA helicase A), an important regulator of transcription, translation, and genomic stability.1 ATX968 selectively kills microsatellite instable colorectal cancer cells with deficient mismatch repair, but not microsatellite stable cells with proficient mismatch repair.2 Active in mouse xenograft (LS411N and SW480) models of microsatellite instable colorectal cancer.

References/Citations:

  1. Daniels et al. (2025), Discovery of ATX968: An Orally Available Allosteric Inhibitor of DHX9; J. Med. Chem. 68 9537
  2. Castro et al. (2025), A Potent, Selective, Small-Molecule Inhibitor of DHX9 Abrogates Proliferation of Microsatellite Instable Cancers with Deficient Mismatch Repair; Cancer Res. 85 758